Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
25 hedge funds and large institutions have $62.4M invested in Urovant Sciences Ltd. in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
4% more funds holding
Funds holding: 24 → 25 (+1)
3.21% less ownership
Funds ownership: 23.81% → 20.59% (-3.2%)
7% less capital invested
Capital invested by funds: $67M → $62.4M (-$4.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
+$1.42M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.32M |
| 3 |
Renaissance Technologies
New York
|
+$1.05M |
| 4 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$978K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.46M |
| 2 |
First Manhattan
New York
|
-$2.11M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$2.07M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.73M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$86.1K |
UROV Hedge Fund Activity: Q2 2020 in Review
25 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q2 2020, worth a combined $62.4M — down 6.8% from $67M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new UROV positions and 7 closed out — a net gain of 1 holder — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Pekin Hardy Strauss, adding an estimated $1.42M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $8.46M sold.
- 25 institutional investors held Urovant Sciences Ltd. (UROV) as of Q2 2020, up from 24 in Q1 2020.
- Funds reported $62.4M of Urovant Sciences Ltd. stock for Q2 2020, down 6.8% quarter-over-quarter.
- 8 funds opened new Urovant Sciences Ltd. positions in Q2 2020 and 7 closed out, a net change of +1 holder.
- The largest Urovant Sciences Ltd. buyer in Q2 2020 was Pekin Hardy Strauss, an estimated $1.42M added.
- The largest Urovant Sciences Ltd. seller in Q2 2020 was Adage Capital Partners, an estimated $8.46M sold.
Based on aggregated 13F filings for Q2 2020.